ReviewVirulence2025
Pathogenicity and virulence of Kyasanur Forest disease: A comprehensive review of an expanding zoonotic threat in southwestern India.
Review in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiology of Kyasanur forest disease in India, 2000-2025: a systematic review and meta-analysis.The Lancet regional health. Southeast Asia · 2026Article
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- Development of whole virion inactivated Kyasanur Forest Disease vaccine candidate and its preclinical safety and efficacy evaluation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kyasanur Forest Disease (KFD) is a tick-borne viral hemorrhagic fever caused by the KFD virus (KFDV). First identified in 1957 in Karnataka, India, KFD primarily affects humans and non-human primates. The disease has a broad clinical manifestation, ranging from asymptomatic infections to severe hemorrhagic complications, with a mortality rate of 3-10%. Over time, KFD has shown a gradual geographical expansion, with cases now reported beyond Karnataka. KFD has been a public health challenge for nearly seven decades, as no effective vaccine or antivirals are available. Although humoral immunity is critical in controlling KFD infection, with neutralizing antibodies conferring durable protection, the role of cellular immunity is not well studied. Preventive strategies - such as tick control, community education, and well-planned surveillance - are vital to reducing disease burden. This review synthesizes knowledge on KFD, encompassing its discovery, epidemiology, clinical presentations, diagnostic assays, viral evolution, pathophysiology, immune mechanisms, interventions, and research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.